Immuneering Corporation
NASDAQ:IMRXBiotechnology
Healthcare
$3.50 -0.14%
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
52W Low $2.29High $10.08
Volume 0.73M
Average 1.38M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$59.38M
FY 2025 · Annual
Net Income
-$56.02M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.08M | 316.95K | 0 | 0 | 0 |
| Cost of Revenue | 1.15M | 158.12K | 0 | 0 | 698.89K |
| Gross Profit | 926.89K | 158.83K | 0 | 0 | (698.89K) |
| Gross Margin | 44.6% | 50.1% | — | — | — |
| Research & Development | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
| Selling, General & Admin | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M |
| Operating Expenses | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M |
| Depreciation & Amortization | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K |
| EBITDA | (33.68M) | (51.47M) | (58.06M) | (63.69M) | (55.33M) |
| EBITDA Margin | -1619.5% | -16238.4% | — | — | — |
| Operating Income | (33.89M) | (51.74M) | (58.41M) | (64.07M) | (59.38M) |
| Operating Margin | -1629.2% | -16325.8% | — | — | — |
| Interest Income | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M |
| Income Before Tax | (33.84M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Pre-Tax Margin | -1627.1% | -15937.4% | — | — | — |
| Income Tax Expense | (307.49K) | 0 | 0 | 0 | 0 |
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Net Margin | -1612.3% | -15937.3% | — | — | — |
| EPS (Basic) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| EPS (Diluted) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| 26.32M | 26.39M | 28.42M | 29.98M | 44.01M | |
| 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
IMRX Earnings Waterfall · TTM
NASDAQ:IMRX · Revenue to Net Income
Key Ratios
EPS$-1.17
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$54.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.17, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 |
How much revenue does IMRX generate?
Immuneering Corporation (IMRX) reported $0.00 of revenue in fiscal 2025.
Is IMRX profitable?
Immuneering Corporation (IMRX) reported -$56.02M of net income.
Continue the stock analysis
Jump to another research area for this company.